This article was originally published in The Tan Sheet
Hemorrhagic stroke risk is due to abuse of PPA-containing weight loss drugs, not proper use of cough/cold remedies, Michael Ernst and Arthur Hartz, MD/PhD, University of Iowa and William Wolowich, Children's Hospital, Columbus, Ohio, et al., state in letters in April 5 New England Journal of Medicine. "Patients who take [PPA] as a weight-loss aid commonly abuse the drug by taking it in higher-than-recommended doses," Wolowich notes. HSP authors Walter Kernan et al. respond their data showed stroke risk also was linked to proper use of cough/cold OTCs, but acknowledge weight loss doses were higher. NEJM released the HSP's findings last November (1"The Tan Sheet" Nov. 13, 2000, p. 4)
You may also be interested in...
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning